PL363313A1 - Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związki - Google Patents

Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związki

Info

Publication number
PL363313A1
PL363313A1 PL02363313A PL36331302A PL363313A1 PL 363313 A1 PL363313 A1 PL 363313A1 PL 02363313 A PL02363313 A PL 02363313A PL 36331302 A PL36331302 A PL 36331302A PL 363313 A1 PL363313 A1 PL 363313A1
Authority
PL
Poland
Prior art keywords
deuterated
piperidinopropiophenones
illnesses
muscular
treatment
Prior art date
Application number
PL02363313A
Other languages
English (en)
Inventor
Rudolf-Gisbert Alken
Thomas Stabingis
Original Assignee
Turicum Drug Development Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turicum Drug Development Ag filed Critical Turicum Drug Development Ag
Publication of PL363313A1 publication Critical patent/PL363313A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
PL02363313A 2001-05-02 2002-04-29 Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związki PL363313A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10123129A DE10123129A1 (de) 2001-05-02 2001-05-02 Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
PCT/DE2002/001607 WO2002088100A2 (de) 2001-05-02 2002-04-29 Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
PL363313A1 true PL363313A1 (pl) 2004-11-15

Family

ID=7684543

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363313A PL363313A1 (pl) 2001-05-02 2002-04-29 Deuterowane 3-piperydynopropiofenony oraz środki lecznicze zawierające te związki

Country Status (22)

Country Link
US (1) US7307091B2 (pl)
EP (1) EP1383752B1 (pl)
JP (1) JP4373097B2 (pl)
KR (1) KR100894846B1 (pl)
CN (2) CN101002770A (pl)
AT (1) ATE298324T1 (pl)
AU (1) AU2002257562B2 (pl)
CA (1) CA2446890C (pl)
CZ (1) CZ20033060A3 (pl)
DE (2) DE10123129A1 (pl)
DK (1) DK1383752T3 (pl)
ES (1) ES2244768T3 (pl)
HU (1) HUP0400077A2 (pl)
IL (1) IL158668A0 (pl)
IS (1) IS7006A (pl)
NO (1) NO20034863L (pl)
NZ (1) NZ529586A (pl)
PL (1) PL363313A1 (pl)
PT (1) PT1383752E (pl)
RU (1) RU2296755C2 (pl)
SI (1) SI1383752T1 (pl)
WO (1) WO2002088100A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
DE102005014080B4 (de) * 2005-03-21 2007-11-22 Birds Pharma Gmbh Berolina Innovative Research & Development Services Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel
CA2615670C (en) * 2005-07-26 2015-01-20 Nycomed Gmbh Isotopically substituted proton pump inhibitors
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
JP5289951B2 (ja) * 2005-07-26 2013-09-11 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 同位体置換されたパントプラゾール
JP2009511481A (ja) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 増強された治療特性を持つ、胃Ｈ＋，Ｋ＋−ＡＴＰａｓｅの重水素化阻害剤
MX2008014450A (es) 2006-05-18 2009-03-09 Mannkind Corp Inhibidores de cinasa intracelular.
CN101547696A (zh) * 2006-08-08 2009-09-30 奥斯拜客斯制药有限公司 具有α肾上腺素能阻断效应的取代喹唑啉化合物的制备和应用
WO2012028635A1 (en) * 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CA2932610C (en) 2013-12-03 2023-08-22 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia
PL3125893T3 (pl) 2014-04-04 2024-02-12 Intra-Cellular Therapies, Inc. Deuterowane gamma-karboliny w fuzji z heterocyklami jako antagoniści receptorów 5-HT2A
WO2017105881A1 (en) * 2015-12-15 2017-06-22 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
PT3407889T (pt) 2016-03-25 2021-07-14 Intra Cellular Therapies Inc Compostos orgânicos e a sua utilização no tratamento ou prevenção de distúrbios do sistema nervoso central
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106588817A (zh) * 2016-12-13 2017-04-26 湖南亚大制药有限公司 一种盐酸乙哌立松的合成方法
AU2018240540B2 (en) 2017-03-24 2021-09-23 Intra-Cellular Therapies, Inc. Novel compositions and methods
US10695345B2 (en) 2018-08-31 2020-06-30 Intra-Cellular Therapies, Inc. Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
JP2021536453A (ja) 2018-08-31 2021-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規方法
CN110845443B (zh) * 2019-12-11 2023-09-05 嘉实（湖南）医药科技有限公司 一种制备高纯度盐酸托哌酮的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5527914B2 (pl) * 1973-12-14 1980-07-24
US3995047A (en) * 1973-12-14 1976-11-30 Eisai Co., Ltd. Propiophenone derivatives in the treatment of pathological muscular conditions
HU33131A (pl) * 1984-01-26 1984-10-29

Also Published As

Publication number Publication date
KR20040015240A (ko) 2004-02-18
CA2446890C (en) 2010-02-23
WO2002088100A2 (de) 2002-11-07
ES2244768T3 (es) 2005-12-16
RU2003133924A (ru) 2005-05-10
WO2002088100A3 (de) 2003-05-30
SI1383752T1 (sl) 2005-12-31
IL158668A0 (en) 2004-05-12
JP2004527558A (ja) 2004-09-09
NZ529586A (en) 2005-07-29
NO20034863D0 (no) 2003-10-31
CN101002770A (zh) 2007-07-25
EP1383752B1 (de) 2005-06-22
HUP0400077A2 (hu) 2004-04-28
EP1383752A2 (de) 2004-01-28
PT1383752E (pt) 2005-11-30
AU2002257562B2 (en) 2007-01-11
RU2296755C2 (ru) 2007-04-10
CZ20033060A3 (cs) 2004-09-15
DE10123129A1 (de) 2002-11-14
DE50203456D1 (de) 2005-07-28
IS7006A (is) 2003-10-30
US7307091B2 (en) 2007-12-11
KR100894846B1 (ko) 2009-04-24
ATE298324T1 (de) 2005-07-15
CN1527823A (zh) 2004-09-08
CA2446890A1 (en) 2002-11-07
DK1383752T3 (da) 2005-10-17
NO20034863L (no) 2003-12-30
CN1293064C (zh) 2007-01-03
US20040186136A1 (en) 2004-09-23
JP4373097B2 (ja) 2009-11-25

Similar Documents

Publication Publication Date Title
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2004112711A3 (en) Oral extended-release composition
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
SE9901573D0 (sv) New compounds
HK1068606A1 (en) Novel aminobenzoephenones
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
SE0102440D0 (sv) New compound
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
CA2385755A1 (en) Prevention of colorectal cancer

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)